Abstract
Antimitotic agents have been the most successful pharmacological agents for the treatment of cancer. The term "antimitotic agent" has traditionally been synonymous with tubulin-targeting compounds, but as a consequence of the large number of new compounds and mechanisms that have been identified recently, a much broader definition is currently needed. This review attempts to provide a broad overview of compounds and their cognate protein targets which result in a block in mitosis. Focus has been placed on agents that act directly on the mitotic machinery rather than on targets further upstream such as growth factor receptors.
MeSH terms
-
Actins / metabolism
-
Animals
-
Antimitotic Agents / classification
-
Antimitotic Agents / pharmacology*
-
Binding Sites / drug effects
-
Biological Products / classification
-
Biological Products / pharmacology*
-
Colchicine / pharmacology
-
Enzyme Inhibitors / pharmacology
-
Histone Deacetylase Inhibitors
-
Humans
-
Kinesins / antagonists & inhibitors
-
Microtubule Proteins / antagonists & inhibitors
-
Phosphoric Monoester Hydrolases / antagonists & inhibitors
-
Phosphoric Monoester Hydrolases / genetics
-
Proteasome Inhibitors
-
Sulfhydryl Compounds / pharmacology
-
Topoisomerase Inhibitors
-
Tubulin / drug effects
-
Vinca Alkaloids / pharmacology
Substances
-
Actins
-
Antimitotic Agents
-
Biological Products
-
Enzyme Inhibitors
-
Histone Deacetylase Inhibitors
-
Microtubule Proteins
-
Proteasome Inhibitors
-
Sulfhydryl Compounds
-
Topoisomerase Inhibitors
-
Tubulin
-
Vinca Alkaloids
-
Phosphoric Monoester Hydrolases
-
Kinesins
-
Colchicine